Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 1b/2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for Patients With HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma

NCT07529613 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT07529613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07529613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 1b/2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for Patients With HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 1/2
Overall status
Completed
Start date
December 20, 2023
Completion date
December 31, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal junction adenocarcinoma